Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Bertolini

Showing results (111-120 of 169) with videos related to

Pageof 17
Sort By:
Experimental Cell Research|March 31, 2004
Skeletal muscle differentiation potential of human adult bone marrow cellsPatrizia Bossolasco, Stefania Corti, Sandra Strazzer, et al.
British Journal of Haematology|August 16, 2002
Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patientsGiancarlo Pruneri, Maurilio Ponzoni, Andrés J M Ferreri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 15, 2015
A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid TumorsLaura W Goff, Roger B Cohen, Jordan D Berlin, et al.
Nature Communications|March 23, 2024
BET inhibitors drive Natural Killer activation in non-small cell lung cancer via BRD4 and SMAD3Francesca Reggiani, Giovanna Talarico, Giulia Gobbi, et al.
Stem Cells (Dayton, Ohio)|October 5, 2023
Bitter Taste Receptor Agonist Denatonium Inhibits Stemness Characteristics in Hematopoietic Stem/Progenitor CellsValentina Pensato, Maria Antonella Laginestra, Paolo Falvo, et al.
Clinical Breast Cancer|April 24, 2012
Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activityEmilia Montagna, Giuseppe Cancello, Vincenzo Bagnardi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2006
High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphomaRena Buckstein, Robert S Kerbel, Yuval Shaked, et al.
Blood|September 30, 2006
The extracellular nucleotide UTP is a potent inducer of hematopoietic stem cell migrationLara Rossi, Rossella Manfredini, Francesco Bertolini, et al.
Cancers|May 14, 2025
Germline Testing in Breast Cancer: A Single-Center Analysis Comparing Strengths and Challenges of Different ApproachesMonica Marabelli, Mariarosaria Calvello, Elena Marino, et al.
Molecular Cancer Therapeutics|February 11, 2015
The Combination of the PARP Inhibitor Rucaparib and 5FU Is an Effective Strategy for Treating Acute LeukemiasMaria Vittoria Verga Falzacappa, Chiara Ronchini, Mario Faretta, et al.
Pageof 17

Showing results (111-120 of 169) with videos related to

Sort By:
Pageof 17
Experimental Cell Research|March 31, 2004
Skeletal muscle differentiation potential of human adult bone marrow cellsPatrizia Bossolasco, Stefania Corti, Sandra Strazzer, et al.
British Journal of Haematology|August 16, 2002
Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patientsGiancarlo Pruneri, Maurilio Ponzoni, Andrés J M Ferreri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 15, 2015
A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid TumorsLaura W Goff, Roger B Cohen, Jordan D Berlin, et al.
Nature Communications|March 23, 2024
BET inhibitors drive Natural Killer activation in non-small cell lung cancer via BRD4 and SMAD3Francesca Reggiani, Giovanna Talarico, Giulia Gobbi, et al.
Stem Cells (Dayton, Ohio)|October 5, 2023
Bitter Taste Receptor Agonist Denatonium Inhibits Stemness Characteristics in Hematopoietic Stem/Progenitor CellsValentina Pensato, Maria Antonella Laginestra, Paolo Falvo, et al.
Clinical Breast Cancer|April 24, 2012
Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activityEmilia Montagna, Giuseppe Cancello, Vincenzo Bagnardi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2006
High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphomaRena Buckstein, Robert S Kerbel, Yuval Shaked, et al.
Blood|September 30, 2006
The extracellular nucleotide UTP is a potent inducer of hematopoietic stem cell migrationLara Rossi, Rossella Manfredini, Francesco Bertolini, et al.
Cancers|May 14, 2025
Germline Testing in Breast Cancer: A Single-Center Analysis Comparing Strengths and Challenges of Different ApproachesMonica Marabelli, Mariarosaria Calvello, Elena Marino, et al.
Molecular Cancer Therapeutics|February 11, 2015
The Combination of the PARP Inhibitor Rucaparib and 5FU Is an Effective Strategy for Treating Acute LeukemiasMaria Vittoria Verga Falzacappa, Chiara Ronchini, Mario Faretta, et al.
Pageof 17